In connection with the Company's preferential rights issue of units carried out earlier in 2024, 45.082.580 warrants of series TO 1 were issued. Holders of TO 1 have the right to subscribe for one (1) new share in Diagonal Bio at a price of SEK 0,05 per share during the exercise period, which runs until the 26th of September 2024.

In order for warrants not to expire without value, the holder is required to subscribe for new shares, by exercising warrants, no later than 17:00 on the 26th of September 2024, or sell warrants no later than on the 24th of September 2024.

An information brochure about the Company and the offer is available on the respective websites of Diagonal Bio (www.diagonalbio.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se). Complete terms and instructions for warrants of series TO 1 are available on the Company's website.

Advisors
In connection with the warrant exercise, Diagonal Bio has engaged Sedermera Corporate Finance AB as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent.

For more information about the warrants, please contact:

Sedermera Corporate Finance AB

Phone: +46 (0) 40 615 14 10

E-mail: cf@sedermera.se

www.sedermera.se

For more information, please contact:

Karin Wehlin, CEO

Phone: +46 (0)70305 24 88

E-mail: kw@diagonalbio.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

E-mail: ca@skmg.se

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.